Survey Finds Cimzia Prescriptions for nr-axSpA on the Rise in US
From: Ankylosing Spondylitis News By: Patricia Inacio, PhD. According to Spherix Global Insights’ survey, which was conducted in March, the main barriers to prescribing Cimzia for nr-axSpA in the U.S. were insurance and cost issues. However, the number of rheumatologists citing these as obstacles has significantly decreased year after year, which highlights the potential widespread […]
UCB’s Cimzia is Making Inroads in the Treatment of Axial Disease, with Significant Uptake in Non-Radiographic Axial Spondyloarthritis and a Positive Treatment Halo in Ankylosing Spondylitis
In AS, the IL-17 inhibitors are beginning to challenge the leading TNF inhibitors, but rheumatologists struggle to differentiate Novartis’ Cosentyx and Eli Lilly’s Taltz, according to a new report by Spherix Global Insights EXTON, Pa., April 29, 2020 /PRNewswire/ — The recent approval of UCB’s TNF inhibitor, Cimzia, for the treatment of non-radiographic axial spondyloarthritis […]
Specialty Physicians Predict More Pain Ahead in the Battle Against COVID-19
The impact to practices has been severely disruptive, taking a devastating personal and financial toll on specialty physicians according to the latest update from Spherix Global Insights EXTON, Pa., April 9, 2020 / PRNewswire / – Special Report: Multi-Specialty Impact of COVID-19 is an independent project being run by Spherix to assess the impact of […]
COVID-19 Wreaking Havoc in Specialty Practices and the Vast Majority of Physicians Expect It to Get Worse in the Next Two Weeks, According to a New Report by Spherix Global Insights
Results from a survey of more than 300 dermatologists, gastroenterologists, nephrologists, neurologists, rheumatologists, and primary care physicians indicate a marked decrease in patient visits, growing concern over financial impact to practices, and worry over preparedness for a widespread local outbreak EXTON, Pa., March 24, 2020 / PRNewswire / – Spherix Global Insights is an independent […]
AbbVie Prompts Patients to ‘take on’ Arthritis in First Rinvoq DTC Ad
From: FiercePharma By: Beth Snyder Bulik AbbVie Prompts Patients to ‘take on’ Arthritis in First Rinvoq DTC Ad While Xeljanz still enjoys support from rheums given the drug’s seven-year commercial history, docs indicated Rinvoq as the most preferred JAK if only one were to be prescribed, citing safety, efficacy and breadth of data all as […]
AbbVie’s Rinvoq continues march with NICE nod in rheumatoid arthritis
From: FiercePharma By: Kyle Blankenship AbbVie’s Rinvoq Continues March with NICE Nod in Rheumatoid Arthritis In December, a rheumatologist survey conducted by Spherix Global Insights showed about half of 100 physicians would prescribe Rinvoq over other JAK inhibitors, specifically citing AbbVie’s “stewardship” of the drug as a positive for prescribing, Piper analyst Christopher Raymond […]
Promising Early Launch Metrics for AbbVie’s Rinvoq (upadacitinib) to Help JAK Inhibitors Solidify Their Position as Second-Line Leaders in Rheumatoid Arthritis, According to Spherix Global Insights
As IL-6 inhibitor use in second- or later-line biologic/JAK therapy in RA declines and TNF class share remains flat, the introduction and positive early readout of the third JAK to market bodes well for the JAK inhibitor class. EXTON, Pa., December 16, 2019 /PRNewswire/ — Spherix examined the charts of 1,021 rheumatoid arthritis (RA) patients recently […]
Pro-AbbVie Bias May be Driving Rheumatologist Confidence in Newcomer Rinvoq: Analyst
From: FiercePharma By: Kyle Blankenship Pro-AbbVie Bias May be Driving Rheumatologist Confidence in Newcomer Rinvoq: Analyst Between AbbVie’s two newly approved blockbusters-in-waiting, psoriasis med Skyrizi’s booming sales have drawn some analysts’ eyes away from highly-touted rheumatoid arthritis drug Rinvoq. But among physicians, Rinvoq is becoming a darling, one analyst […]
Positive Growth of Eli Lilly’s Taltz and Stabilization of Novartis’ Cosentyx in Psoriasis May be an Indicator for Future Psoriatic Arthritis Market Shift
Cosentyx’s first-to-market status in psoriasis, psoriatic arthritis, and ankylosing spondylitis has historically provided the brand with a competitive edge over in-class rival, Taltz, though recent studies conducted by Spherix Global Insights indicate changes are afoot EXTON, Pa., October 10, 2019 /PRNewswire/ — Novartis’ Cosentyx was first approved by the FDA for the treatment of psoriasis in […]
Novartis’ Cosentyx and Pfizer’s Xeljanz Leave the Most on the Table with Psoriatic Arthritis Switch Brands, According to Spherix Global Insights
While the alternate mechanism of action agents are becoming increasingly popular in the second- or later-lines of therapy, they are also forfeiting a substantial amount of potential share EXTON, Pa., September 13, 2019 /PRNewswire/ — The fourth annual patient chart audit included in Spherix’s RealWorld Dynamix™: Biologic/Small Molecule Switching in PsA (US) service includes the feedback […]